[go: up one dir, main page]

MX379327B - Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3 - Google Patents

Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3

Info

Publication number
MX379327B
MX379327B MX2018013701A MX2018013701A MX379327B MX 379327 B MX379327 B MX 379327B MX 2018013701 A MX2018013701 A MX 2018013701A MX 2018013701 A MX2018013701 A MX 2018013701A MX 379327 B MX379327 B MX 379327B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
pyridinyl derivatives
aoc3 inhibitors
aoc3
inhibitors
Prior art date
Application number
MX2018013701A
Other languages
English (en)
Other versions
MX2018013701A (es
Inventor
Andreas Blum
Cédrickx Godbout
Joerg P Hehn
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018013701A publication Critical patent/MX2018013701A/es
Publication of MX379327B publication Critical patent/MX379327B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos derivados de piridinilo de la fórmula (I) (VER FORMULA) en donde R1 y A son como se definen en la descripción y las reivindicaciones, a su uso como medicamentos, a los métodos para su uso terapéutico y a las composiciones farmacéuticas que los contienen.
MX2018013701A 2016-05-12 2017-05-08 Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3 MX379327B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16169356 2016-05-12
PCT/EP2017/060890 WO2017194453A1 (en) 2016-05-12 2017-05-08 Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors

Publications (2)

Publication Number Publication Date
MX2018013701A MX2018013701A (es) 2019-05-02
MX379327B true MX379327B (es) 2025-03-11

Family

ID=55967162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013701A MX379327B (es) 2016-05-12 2017-05-08 Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3

Country Status (32)

Country Link
US (1) US9926292B2 (es)
EP (1) EP3455216B1 (es)
JP (1) JP6639702B2 (es)
KR (1) KR20190003995A (es)
CN (1) CN109153664B (es)
AR (1) AR108462A1 (es)
AU (1) AU2017262707B2 (es)
CA (1) CA3023805A1 (es)
CL (1) CL2018003158A1 (es)
CO (1) CO2018012020A2 (es)
CY (1) CY1123744T1 (es)
DK (1) DK3455216T3 (es)
EA (1) EA037188B1 (es)
ES (1) ES2844926T3 (es)
HR (1) HRP20202078T1 (es)
HU (1) HUE053312T2 (es)
IL (1) IL262662B (es)
JO (1) JOP20170115B1 (es)
LT (1) LT3455216T (es)
MA (1) MA44965B1 (es)
MX (1) MX379327B (es)
PE (1) PE20190151A1 (es)
PH (1) PH12018502376B1 (es)
PL (1) PL3455216T3 (es)
PT (1) PT3455216T (es)
RS (1) RS61256B1 (es)
SA (1) SA518400393B1 (es)
SG (1) SG11201809687TA (es)
SI (1) SI3455216T1 (es)
TW (1) TWI746551B (es)
UA (1) UA121930C2 (es)
WO (1) WO2017194453A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN112789277B (zh) * 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
PE20211467A1 (es) * 2018-10-29 2021-08-05 Boehringer Ingelheim Int Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CA3155114A1 (en) 2019-10-29 2021-05-06 Eccogene (Shanghai) Co., Ltd. Semicarbazide-sensitive amino oxidase inhibitors and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518073A1 (de) * 1995-05-17 1996-11-21 Hoechst Ag Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US8362017B2 (en) * 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
DE602005013793D1 (de) * 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
ES2651690T3 (es) * 2009-09-16 2018-01-29 Astellas Pharma Inc. Compuesto de glicina
HUE028394T2 (en) 2011-03-15 2016-12-28 Astellas Pharma Inc Guanidine compound
WO2017022861A1 (ja) 2015-08-06 2017-02-09 宇部興産株式会社 置換グアニジン誘導体

Also Published As

Publication number Publication date
CN109153664B (zh) 2021-07-16
CO2018012020A2 (es) 2018-11-13
PL3455216T3 (pl) 2021-05-17
HRP20202078T1 (hr) 2021-02-19
KR20190003995A (ko) 2019-01-10
SI3455216T1 (sl) 2021-02-26
UA121930C2 (uk) 2020-08-10
PH12018502376A1 (en) 2019-04-08
SG11201809687TA (en) 2018-11-29
AU2017262707A1 (en) 2018-10-11
HUE053312T2 (hu) 2021-07-28
US20170327483A1 (en) 2017-11-16
TW201805278A (zh) 2018-02-16
MA44965A (fr) 2019-03-20
CN109153664A (zh) 2019-01-04
MX2018013701A (es) 2019-05-02
AR108462A1 (es) 2018-08-22
MA44965B1 (fr) 2021-02-26
CA3023805A1 (en) 2017-11-16
EP3455216B1 (en) 2020-11-04
AU2017262707B2 (en) 2020-11-19
PH12018502376B1 (en) 2021-10-06
PT3455216T (pt) 2021-01-18
SA518400393B1 (ar) 2021-09-08
IL262662A (en) 2018-12-31
EA201892539A1 (ru) 2019-06-28
EA037188B1 (ru) 2021-02-17
WO2017194453A1 (en) 2017-11-16
RS61256B1 (sr) 2021-01-29
NZ746586A (en) 2021-08-27
JP2019519495A (ja) 2019-07-11
TWI746551B (zh) 2021-11-21
LT3455216T (lt) 2021-01-11
PE20190151A1 (es) 2019-01-22
DK3455216T3 (da) 2021-01-18
JOP20170115B1 (ar) 2021-08-17
CL2018003158A1 (es) 2019-01-18
CY1123744T1 (el) 2022-05-27
US9926292B2 (en) 2018-03-27
ES2844926T3 (es) 2021-07-23
JP6639702B2 (ja) 2020-02-05
IL262662B (en) 2021-07-29
EP3455216A1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
PH12018502515A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
PH12021550901A1 (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
GEP201706619B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical composition containing them
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
TW201613864A (en) Novel compounds
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators